CORAL GABLES, FL / ACCESSWIRE / October 23, 2018 / The stock market turned bearish during the early morning hours. International concern drove futures lower before the opening bell on Tuesday. Many investors have begun flocking to safe haven stocks for more protection to their portfolios. However, there are still other investors looking to capitalize on this volatility. Healthcare stocks have helped during times like these. Stocks in this sector have been on fire recently, and ahead of mid-term elections, the industry has also been a topic of discussion for voters. Three healthcare stocks to watch this week include Premier Health Group, Inc. (PHGRF)(PHGI.CN), Neovasc Inc. (NVCN), and Regulus Therapeutics Inc. (RGLS).
Premier Health Group, Inc. (PHGRF)(PHGI.CN), continued to trade higher this week. The stock has been on the rise over the last few trading days, mainly in the Canadian market. In fact, since September 20, shares of the company have moved from lows of CAD$0.50 to as high as CAD$0.88. For Premier Health, the company has made strides to open its publicly traded shares to be more easily traded in the US. The company announced this week that its common shares traded on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol " PHGRF'', are Depository Trust Company ("DTC") eligible, effective October 22, 2018. DTC eligibility allows Premier Health shares to be more easily and economically transferred between brokerage accounts electronically within the United States
Premier Health Group, Inc. (PHGRF)(PHGI.CN), has also focused on expanding through strategic deals with other public health companies. Earlier this month, Premier announced that it has selected Reliq Health Technologies Inc. as its exclusive technology partner. Premier's HealthVue primary care clinics will be provided with a HealthVue-branded telemedicine, remote monitoring & AI solution for its clinical staff and more than 100,000 active patients. Reliq Health Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market.
Neovasc Inc. (NVCN) focuses on the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina. This week the company announced that its Tiara™ transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 32nd Annual European Association for Cardio-Thoracic Surgery Meeting, held October 18-20 in Milan, Italy.
"This live case broadcast reinforced Tiara's potential as a promising treatment option for patients who are unsuitable to receive an open-heart surgical valve replacement," commented Fred Colen, Neovasc's President and Chief Executive Officer in a press release.
The company is working to expand its Tiara clinical program and ultimately the adoption of Tiara for routine use in these patients once regulatory approvals are obtained.
Regulus Therapeutics Inc. (RGLS) saw its shares gapping up during Tuesday morning's premarket trading. The biopharmaceutical company is focused on the discovery and development of innovative medicines targeting microRNAs. Monday, Regulus announced that it will present preclinical data regarding RGLS4326, a single stranded, chemically modified oligonucleotide in clinical development for Autosomal Dominant Polycystic Kidney Disease (ADPKD), at the American Society of Nephrology's (ASN) Kidney Week 2018 meeting being held October 23-28, 2018 in San Diego, CA.
"We are pleased to be making several presentations on our RGLS4326 program during this year's Kidney Week meeting that we believe further demonstrate the compound's novel mechanism and therapeutic potential to treat patients with ADPKD," said Jay Hagan, President and Chief Executive Officer of Regulus.
According to the company, Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2018 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer